Reyon Pharmaceutical Co Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: -0.007x

Reyon Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Reyon Pharmaceutical Co Ltd (102460) has a cash flow conversion efficiency ratio of -0.007x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.73 Billion ≈ $-1.17 Million USD) by net assets (₩233.12 Billion ≈ $157.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Reyon Pharmaceutical Co Ltd (2008–2024)

Cash flow conversion efficiency of Reyon Pharmaceutical Co Ltd from 2008 to 2024. This chart illustrates how Reyon Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Reyon Pharmaceutical Co Ltd stock price today for real-time trading data and today's change.

Reyon Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained

Reyon Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Reyon Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Reyon Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Also see Reyon Pharmaceutical Co Ltd (102460) market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Dongsung Corporation KO:102260	-0.014x
RiverNorth Managed Duration Municipal Income Fund II Inc. NYSE:RMMZ	N/A
Gladiator Metals Corp V:GLAD	-0.429x
Kulmbacher Brauerei Aktien-Gesellschaft MU:KUL	0.001x
Willbes KO:008600	0.151x
Arsan Tekstil Ticaret ve Sanayi AS IS:ARSAN	0.022x
Creative Newtech Limited NSE:CREATIVE	-0.268x
Ilshinstone KO:007110	-0.001x

Annual Cash Flow Conversion Efficiency for Reyon Pharmaceutical Co Ltd (2008–2024)

The table below shows the annual cash flow conversion efficiency of Reyon Pharmaceutical Co Ltd from 2008 to 2024. Review how much free cash does Reyon Pharmaceutical Co Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩249.94 Billion ≈ $169.38 Million	₩-1.44 Billion ≈ $-973.03K	-0.006x	-116.52%
2023-12-31	₩248.62 Billion ≈ $168.49 Million	₩8.65 Billion ≈ $5.86 Million	0.035x	-1.31%
2022-12-31	₩247.77 Billion ≈ $167.91 Million	₩8.73 Billion ≈ $5.92 Million	0.035x	-26.06%
2021-12-31	₩245.24 Billion ≈ $166.19 Million	₩11.68 Billion ≈ $7.92 Million	0.048x	+138.35%
2020-12-31	₩230.09 Billion ≈ $155.93 Million	₩4.60 Billion ≈ $3.12 Million	0.020x	+136.47%
2019-12-31	₩222.29 Billion ≈ $150.64 Million	₩-12.18 Billion ≈ $-8.26 Million	-0.055x	-207.90%
2018-12-31	₩225.39 Billion ≈ $152.74 Million	₩11.45 Billion ≈ $7.76 Million	0.051x	-33.44%
2017-12-31	₩219.66 Billion ≈ $148.86 Million	₩16.76 Billion ≈ $11.36 Million	0.076x	+44.31%
2016-12-31	₩179.10 Billion ≈ $121.37 Million	₩9.47 Billion ≈ $6.42 Million	0.053x	-72.89%
2012-12-31	₩126.36 Billion ≈ $85.63 Million	₩24.65 Billion ≈ $16.70 Million	0.195x	+34.09%
2011-12-31	₩105.47 Billion ≈ $71.48 Million	₩15.34 Billion ≈ $10.40 Million	0.145x	+0.12%
2009-12-31	₩59.76 Billion ≈ $40.50 Million	₩8.68 Billion ≈ $5.88 Million	0.145x	+3.49%
2008-12-31	₩42.63 Billion ≈ $28.89 Million	₩5.99 Billion ≈ $4.06 Million	0.140x	--

About Reyon Pharmaceutical Co Ltd

KO:102460 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$116.84 Million

₩172.41 Billion KRW

Market Cap Rank

#18390 Global

#816 in Korea

Share Price

₩9400.00

Change (1 day)

-0.74%

52-Week Range

₩9360.00 - ₩12570.00

All Time High

₩70413.22